View Older Stories View More Recent Stories

Oct 22, 2024 07:30AM Nvelop Therapeutics to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Oct 22, 2024 07:00AM Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis
Oct 17, 2024 08:00AM Rectify Pharmaceuticals to Present New Preclinical Data at The American Association for the Study of Liver Diseases Annual Meeting
Oct 9, 2024 05:00AM Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US
Oct 7, 2024 07:00AM Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO
Oct 2, 2024 07:00AM Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
Oct 1, 2024 07:00AM Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
Sep 30, 2024 09:00AM Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
Sep 27, 2024 08:04AM Lifordi Named Winner of Endpoints 11 as Developer of Antibody Drug Conjugates for Autoimmune and Inflammatory Diseases
Sep 10, 2024 03:30AM Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
Sep 10, 2024 03:00AM Sofinnova Partners appoints Karl Naegler as Partner
Sep 4, 2024 08:00AM Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical Evaluation of Frevecitinib (KN-002), an Inhaled Pan JAK Inhibitor, in Patients with Moderate to Severe Asthma and COPD via Oral Present
Sep 3, 2024 08:00AM Rectify Pharmaceuticals Appoints Pol Boudes as Chief Medical Officer
Sep 3, 2024 06:32AM Dyne Therapeutics Inc. (DYN) Appoints Doug Kerr as CMO
Sep 3, 2024 06:31AM Dyne Therapeutics Announces Key Leadership Appointments
Aug 29, 2024 06:04AM Form N-PX Atlas Venture Life Scien For: Jun 30
Aug 21, 2024 06:00AM Non-Executive Director Appointment
Aug 9, 2024 06:05AM Form 13F-HR Atlas Venture Life Scien For: Jun 30
Aug 5, 2024 09:23AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Aug 5, 2024 09:23AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 5, 2024 09:22AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 5, 2024 09:22AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 30, 2024 08:00AM BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of Directors
Jul 19, 2024 06:50AM GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 16, 2024 08:00AM Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Jul 16, 2024 08:00AM Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline
Jul 15, 2024 08:00AM Rectify Pharmaceuticals Appoints Bharat Reddy as Chief Business Officer
Jul 9, 2024 04:19PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 9, 2024 04:17PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Jun 28, 2024 07:01AM Verve Therapeutics (VERV) Appoints Nia Tatsis and Jodie Morrison to its Board
Jun 28, 2024 07:00AM Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Jun 28, 2024 07:00AM Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Jun 14, 2024 08:04AM Disc Medicine (IRON) Announces 4.94M Share Offering at $36/sh
Jun 14, 2024 08:03AM Disc Medicine Announces Underwritten Offering of Common Stock
Jun 13, 2024 05:15PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Jun 13, 2024 05:14PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Jun 12, 2024 05:25PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Jun 12, 2024 05:24PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Jun 4, 2024 09:00AM FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B
May 28, 2024 09:00AM Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B
May 21, 2024 04:00PM Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
May 21, 2024 12:15PM Kinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference
May 21, 2024 09:00AM Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
May 21, 2024 03:00AM Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
May 14, 2024 04:03PM Korro Bio (KRRO) Reports Q1, Appoints Kemi Olugemo as Chief Medical Officer
May 14, 2024 04:01PM Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
May 13, 2024 11:57AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2024 11:57AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2024 11:56AM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 13, 2024 11:55AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
View More Recent Stories View Older Stories